A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 2, 2013, Pages 523-530

  Raez, Luis E ^a   Papadopoulos, Kyriakos ^b   Ricart, Alejandro D ^b   Chiorean, E Gabriella ^c   Dipaola, Robert S ^d   Stein, Mark N ^d   Rocha Lima, Caio M ^a   Schlesselman, James J ^a   Tolba, Khaled ^a   Langmuir, Virginia K ^e   Kroll, Stewart ^e   Jung, Donald T ^e   Kurtoglu, Metin ^a   Rosenblatt, Joseph ^a   Lampidis, Theodore J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b CTRC Institute for Drug Development   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e Threshold Pharmaceuticals   (United States)

Author keywords

2 Deoxy d Glucose; Breast cancer; Docetaxel; Head and neck cancers; Lung cancer; Phase I

Indexed keywords

DEOXYGLUCOSE; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; AGITATION; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPOGLYCEMIA; HYPOKALEMIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; SWEATING; T WAVE INVERSION; THROMBOCYTOPENIA; TREATMENT DURATION; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD GLUCOSE; DEOXYGLUCOSE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TAXOIDS;

EID: 84874116164     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2045-1     Document Type: Article

References (28)

1. Hu Y, Moraes C, Savaraj N, Priebe W, Lampidis TJ (2000) Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. Biochem Pharmacol 60(12):1897-1905
2. Liu H, Hu Y, Savaraj N, Priebe W, Lampidis T (2001) Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 40(18):5542-5547
3. Maher J, Krishan A, Lampidis T (2004) Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 53(2):116-122
4. Boutrid H, Jockovich M, Murray T, Piña Y, Feuer W, Lampidis T, Cebulla CM (2008) Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci 49(7):2799-2805
5. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ (2004) 2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64(1):31-34
6. Warburg O (1956) On the origin of the cancer cells. Science 123(1391):309-314
7. Kim J-W, Dang C (2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66(18):8927-8930
8. Shim H, Chun YS, Lewis BC, Dang CV (1998) A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 95(4):1511-1516
9. Ramanathan A, Wang C, Schreiber S (2005) Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 102(17):5992-5997
10. Matoba S, Kang J, Patino W, Wragg A, Boehm M, Gavrilova O, Hurley P, Bunz F, Hwang P (2006) p53 regulates mitochondrial respiration. Science 16(312):1650-1653
11. Landau BR, Laszlo J, Stengle J, Burk D (1958) Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-d-glucose. J Natl Cancer Inst 21(3):485-494
12. Mohanti BK, Rath GK, Anantha N, Kannan V, Das BS, Chandramouli BA, Banerjee AK, Das S, Jena A, Ravichandran R, Sahi UP, Kumar R, Kapoor N, Kalia VK, Dwarakanath BS, Jain V (1996) Improving cancer radiotherapy with 2-deoxy-d-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 35(1):103-111
13. Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, Eddy S, Goodin S, White E, Dipaola RS (2010) Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70(13):1388-1394
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
15. Tsuchida Y, Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37(1):1-3. doi: 10.1002/mpo.1154
16. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (2003). National Cancer Institute
17. Teff KL, Elliott SS, Tschop M, Kieffer TJ, Rader D, Heiman M, Townsend RR, Keim NL, D'Alessio D, Havel PJ (2004) Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab 89(6):2963-2972
18. Duke W, Hirschowitz B, Sachs G (1965) Vagal stimulation of gastric secretion in man by 2-deoxy-d-glucose. Lancet 2(7418):871-876
19. Stalder GA, Schultheiss HR, Allgower M (1972) Use of 2-deoxy-d-glucose for testing completeness of vagotomy in man. Gastroenterology 63(4):552-556
20. Burckhardt D, Stalder GA (1975) Cardiac changes during 2-deoxy-d-glucose test. A study in patients with selective vagotomy and pyloroplasty. Digestion 12(1):1-8
21. Gough AL, Keddie NC (1975) An assessment of the reproducibility and safety of 2-deoxy-d-glucose as a gastric acid stimulant in duodenal ulcer patients. Gut 16(3):171-176
22. Marfella R, Nappo F, De Angelis L, Siniscalchi M, Rossi F, Giugliano D (2000) The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia 43(5):571-575
23. Zhang Y, Han H, Wang J, Wang H, Yang B, Wang Z (2003) Impairment of human ether-a-go-go-related gene (HERG) K + channel function by hypoglycemia and hyperglycemia. Similar phenotypes but different mechanisms. J Biol Chem 278(12):10417-10426
24. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T, Shoshan MC (2008) Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 123(2):476-483
25. Chatterjee S, Hirota H, Belfi CA, Berger SJ, Berger NA (1997) Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78. Cancer Res 57(22):5112-5116
26. Yamada M, Tomida A, Yun J, Cai B, Yoshikawa H, Taketani Y, Tsuruo T (1999) Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Cancer Chemother Pharmacol 44(1):59-64
27. Mese H, Sasaki A, Nakayama S, Yokoyama S, Sawada S, Ishikawa T, Matsumura T (2001) Analysis of cellular sensitization with cisplatin-induced apoptosis by glucose-starved stress in cisplatin-sensitive and -resistant A431 cell line. Anticancer Res 21(2A):1029-1033
28. Singh SP, Gao Y, Singh LD, Kunapuli SP, Ravindra R (1998) Role of microtubules in glucose uptake by C6 glioma cells. Pharmacol Toxicol 83(2):83-89